News for IPSC Stock

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025 Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit Century Therapeutics Announces Leadership Changes Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates Century Therapeutics to Present at the AACR Annual Meeting 2023 Century Therapeutics to Present at Upcoming Investor Conferences Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas Century Therapeutics to Present at Upcoming Investor Conferences Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022 Century Therapeutics to Present at the SITC 37th Annual Meeting Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors Century Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates Century Therapeutics Announces Its Addition to the Russell Microcap® Index Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022 Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates Century Therapeutics to Present at Upcoming Investor Conferences Century Therapeutics to Present at the ASGCT 25th Annual Meeting Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021 Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021 Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Century Therapeutics Added to the NASDAQ Biotechnology Index Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering Century Therapeutics Announces Its Addition to the Russell 2000® Index Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Century Therapeutics Announces Pricing of Initial Public Offering